{"id":5644,"date":"2014-04-01T09:00:00","date_gmt":"2014-04-01T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/"},"modified":"2024-09-23T11:22:42","modified_gmt":"2024-09-23T11:22:42","slug":"meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/","title":{"rendered":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte"},"content":{"rendered":"Breakthrough T1D gaat extra fondsen steken in de ontwikkeling van de inkapselingtherapie van ViaCyte. ViaCyte is een bedrijf in geneesmiddelen, wat zich al enige tijd bezig houdt met de ontwikkeling van VC-01: celtherapie voor inkapseling van b\u00e8tacellen, om zo Type 1 Diabetes te behandelen. De financiering van Breakthrough T1D zal ervoor zorgen dat de overgang naar de klinische testfase van de ontwikkeling soepel verloopt. Het VC-01 product is een inkapselingtherapie die voor een alternatieve bron van insulineproducerende cellen zorgt. Hierdoor zouden mensen met Type 1 Diabetes niet langer afhankelijk zijn van externe insuline.\n\n<a href=\"http:\/\/jdrf.org\/press-releases\/jdrf-to-provide-additional-support-for-upcoming-clinical-trial-of-viacytes-encapsulated-cell-therapy-for-type-1-diabetes\/\">Lees meer&#8230;<\/a> (Engelse site)","protected":false,"raw":""},"excerpt":{"rendered":"<p>Breakthrough T1D gaat extra fondsen steken in de ontwikkeling van de inkapselingtherapie van ViaCyte. ViaCyte is een bedrijf in geneesmiddelen, wat zich al enige tijd bezig houdt met de ontwikkeling van VC-01: celtherapie voor inkapseling van b\u00e8tacellen, om zo Type 1 Diabetes te behandelen. De financiering van Breakthrough T1D zal ervoor zorgen dat de overgang [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5644","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Breakthrough T1D gaat extra fondsen steken in de ontwikkeling van de inkapselingtherapie van ViaCyte. ViaCyte is een bedrijf in geneesmiddelen, wat zich al enige tijd bezig houdt met de ontwikkeling van VC-01: celtherapie voor inkapseling van b\u00e8tacellen, om zo Type 1 Diabetes te behandelen. De financiering van Breakthrough T1D zal ervoor zorgen dat de overgang [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-01T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:42+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte\",\"datePublished\":\"2014-04-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\"},\"wordCount\":106,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\",\"name\":\"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2014-04-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/","og_locale":"nl_NL","og_type":"article","og_title":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D","og_description":"Breakthrough T1D gaat extra fondsen steken in de ontwikkeling van de inkapselingtherapie van ViaCyte. ViaCyte is een bedrijf in geneesmiddelen, wat zich al enige tijd bezig houdt met de ontwikkeling van VC-01: celtherapie voor inkapseling van b\u00e8tacellen, om zo Type 1 Diabetes te behandelen. De financiering van Breakthrough T1D zal ervoor zorgen dat de overgang [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-04-01T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:42+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte","datePublished":"2014-04-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:42+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/"},"wordCount":106,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/","name":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2014-04-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:42+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/meer-jdrf-financiering-voor-ontwikkeling-van-inkapselingtherapie-viacyte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Meer Breakthrough T1D financiering voor inkapselingstherapie ViaCyte"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5644"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5644\/revisions"}],"predecessor-version":[{"id":7208,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5644\/revisions\/7208"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}